We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Dates for shares and ADRs in Accustem

2 Jul 2021 12:30

RNS Number : 0389E
Accustem Sciences Limited
02 July 2021
 

Accustem Sciences Limited

("Accustem" or the "Company")

Distribution Dates for shares and ADRs in Accustem Sciences Limited

Accustem Sciences Limited is pleased to announce that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC were declared effective on 1 July 2021, enabling the completion of the in specie distribution and spin out of Accustem from Tiziana Life Sciences plc. The SEC filings can be viewed at https://sec.report/CIK/0001850767 and there is also a link to them on the Accustem website: www.accustem.com.

If you held ordinary shares in Tiziana Life Sciences plc ("Tiziana") on the UK Record Date

The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated form is as follows:

Demerger Record Time: 7:00 a.m. on 30 October 2020

Ex-entitlement date for Accustem Shares: 2 November 2020

CREST accounts credited with Accustem Shares: 8 July 2021*

Certificates for Accustem Shares for those shareholders

holding their Tiziana Life Sciences plc in certificated form: by 18 July 2021

* replacing allocation placeholders currently showing

If you held Tiziana ADSs (traded on the US Nasdaq Market) on the DR Record Date

The timetable for the holders of Tiziana ADSs (traded on the Nasdaq market) is set out below. You should also review the notice posted by JP Morgan, the ADR depositary bank, which can be found at https://www.adr.com/drprofile/88875G101

Announcement Tiziana CUSIP: 88875G101

Corporate Action Type: Spin Off with DR Distribution

Spin Off Issuer Name: Accustem Sciences Limited

Spin Off DR CUSIP: 00442Y101

DR Distribution Rate: 1 new Accustem DR(s) issued for every 1 existing Tiziana DR held on DR Record Date

Tax Withholding Rate: n/a

DR Record Date: November 6, 2020

DR Payment Date: July 14, 2021

DR Issuance and Cancellation Books close Date: October 28, 2020

DR Issuance and Cancellation Books reopen Date: July 19, 2021

Fees: Issuance fee: $nil per DR issued

This will formally conclude the separation of Accustem from Tiziana Life Sciences plc and no further information concerning Accustem will be published on the Tiziana website. Regular updates will be posted to the Accustem website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZGGNGZFGMZM
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.